ClinicalTrials.gg

Program

brivekimig

Also written as “SAR442970” and “Brivekimig”.

In Sanofi's pipeline, TNFaxOX40L Nanobody VHH. Its studies are mostly in Hidradenitis Suppurativa · Glomerulosclerosis, Focal Segmental · Crohn Disease · Colitis, Ulcerative · Diabetes Mellitus, Type 1, led by Sanofi.

Furthest: phase 2, since Apr 28, 20236 company-led studies, 5 open or runningNext primary completion: Dec 17, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi65 open or runningphase 2since Apr 28, 2023Apr 28, 2023Dec 17, 2026phase 2 · NCT06958536
  • Named in Sanofi’s own pipeline as brivekimig, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2023First study: phase 2 study in Hidradenitis SuppurativaFirst studyNCT05849922 · 86 enrolled · United States, Australia, Belgium and more
  2. Jul 8, 2024Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702 · 84 planned · United States, Argentina, Australia and more
  3. Jan 31, 2025Phase 2 study in Diabetes Mellitus, Type 1NCT06812988 · 84 enrolled · United States, Argentina, Australia and more
  4. Apr 25, 20252 phase 2 studiesNCT06958536, NCT06975722
  5. Sep 5, 2025Phase 2 study in Hidradenitis SuppurativaNCT07170917 · 208 planned · United States, Australia, Canada and more

Ahead

  1. Dec 17, 2026Primary completion: phase 2 study in Colitis, UlcerativeNCT06975722
  2. Dec 17, 2026Primary completion: phase 2 study in Crohn DiseaseNCT06958536
  3. Dec 23, 2026Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT06500702
  4. Feb 9, 2027Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07170917

TargetBeta

“TNFaxOX40L Nanobody VHH”the company's pipeline, read by Claude · source

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07170917Hidradenitis Suppurativa · United States, Australia, Canada and more2RecruitingFeb 9, 2027208
NCT06975722Colitis, Ulcerative · United States, Australia, China and more2Active, not recruitingDec 17, 2026105
NCT06958536Crohn Disease · United States, Australia, Belgium and more2RecruitingDec 17, 202699
NCT06812988Diabetes Mellitus, Type 1 · United States, Argentina, Australia and more2Active, not recruitingApr 29, 202784
NCT06500702Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more2RecruitingDec 23, 202684
NCT05849922Hidradenitis Suppurativa · United States, Australia, Belgium and more2CompletedAug 22, 202486

How it is read

Names in the registry

  • “brivekimig”, 2 entries
  • “SAR442970”, 2 entries
  • “Brivekimig”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.